Organ Preservation Solution Market
Strategic Initiatives by Market Players Expected to Provide Opportunities to Organ Preservation Solution Market
Various market players focus on product launches or strategic collaborations to develop advanced products that help ease the treatment of chronic disorders. There have been various recent developments, such as product launches, mergers, and acquisitions in recent years.
• In April 2022, TransMedics Group, Inc. received premarket FDA approval for its OCS Heart System for using it with organs procured from donors after circulatory death. The OCS Heart System is approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donors-after-circulatory-death (DCD) hearts.
• In August 2023, Paragonix Technologies, a leading organ transplant company, received FDA clearance for its next-generation donor lung preservation system—BAROguard. The BAROguard system combines Paragonix’s advanced hypothermic preservation technology with automated continuous and active airway pressure control. This control ensures the maintenance of an optimal temperature range and a clinically recommended inflation pressure range for donors’ lungs throughout their transfer from donors to recipients. This novel combination of advanced technologies further reinforces the company’s ongoing commitment to improving and redefining the standard of care within the field of transplant medicine.
Thus, a surge in product approvals, launches, and strategic collaborations is likely to create considerable growth opportunities for the organ preservation solution market in the future.
Based on geography, the organ preservation solution market is segmented into North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America is the largest shareholder in the global market, and the US held the largest share of the market in North America in 2023. Europe is the second-largest contributor to the global organ preservation solution market, followed by Asia Pacific.
Germany is expected to be among the major contributors to the growth of the organ preservation solution market worldwide. As per the “World Population Ageing,” nearly 28.0% of the total population of Germany was aged 60 and above in 2017, and the aging population is estimated to rise to nearly 37.6% by 2050. The prevalence of chronic diseases increases with age. Also, with growing age, many organs start to malfunction or become dysfunctional, giving rise to the demand for organ transplantation procedures. Thus, with the rising geriatric population, the demand for organ preservation solutions is growing.
The organ preservation solution market has been segmented on the basis of product, type, application, and end user.
Based on product, the organ preservation solution market is segmented into University of Wisconsin Solution, Custodiol HTK, Perfadex, Hypothermosol, and others. The University of Wisconsin Solution segment held the largest market share in 2023. The hyperthermosol segment is expected to record the fastest CAGR in the market during the forecast period. The projected market growth of this segment is attributed to an increasing number of cardiovascular surgeries, liver transplantation, and kidney transplantation.
By type, the market is segmented into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest share of the market in 2023. The heart segment is estimated to register the highest CAGR during the forecast period.
By application, the market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest share of the market in 2023. The normothermic machine perfusion segment is expected to register the fastest CAGR from 2024 to 2031.
Based on end user, the market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment dominated the market in 2023. The same segment is expected to account for highest CAGR from 2024 to 2031.
Organ Preservation Solution Market: Competitive Landscape and Key Developments
Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, ST CENTURY MEDICINE, Shanghai Genext Pharmaceutical Technology, and Bridge to Life Ltd are among the leading companies profiled in the organ preservation solution market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem. These companies focus on geographic expansions and new product launches to meet the surging demand from consumers worldwide and increase their product range in specialty portfolios. Their global presence allows them to serve a large customer base, subsequently facilitating market expansion.
A few of the developments in the organ preservation solution market are listed below:
- In February 2024, Bridge to Life has reintroduced EasiSlush to the US market, meeting high demand for easy-to-use sterile slush for organ transplantation. EasiSlush is renowned for its ease of use, high quality, and portability, making it the preferred choice for organ transplant professionals.
- In March 2024, OrganOx partnered with Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases. As part of the partnership, OrganOx supplied metra devices to Ochre Bio and its partners for evaluating novel RNA therapeutics using discarded donor livers.
